DARBEX-25 1PFS

About

DARBEX-25 1PFS contains Darbepoetin alfa, an erythropoiesis-stimulating agent (ESA) provided in a pre-filled syringe for convenient administration. It is indicated for the treatment of anemia associated with chronic kidney disease (CKD) in both patients on dialysis and those not yet on dialysis. Darbepoetin alfa functions by stimulating the bone marrow to produce red blood cells, mimicking the action of the naturally occurring hormone erythropoietin. This helps to correct anemia, which is a common and debilitating complication of CKD.

The extended half-life of Darbepoetin alfa allows for less frequent dosing schedules compared to other ESAs, which can significantly improve patient adherence and reduce the burden of injections. By effectively raising and maintaining hemoglobin levels within a target range, DARBEX-25 helps to alleviate symptoms such as fatigue, weakness, and shortness of breath, thereby enhancing the patient's overall quality of life and reducing the need for blood transfusions. Regular monitoring of hemoglobin and blood pressure is essential during therapy.

Uses

• Treatment of anemia associated with chronic kidney disease (CKD)
• Reducing the need for red blood cell transfusions
• Improving hemoglobin levels in renal patients
• Enhancing quality of life for anemic CKD patients

Directions For Use

Administer via subcutaneous or intravenous injection as directed by a healthcare professional. Dosage and frequency are individualized.

Benefits

• Corrects anemia effectively
• Reduces reliance on blood transfusions
• Improves energy levels and reduces fatigue
• Enhances physical capacity and quality of life
• Supports cardiovascular health by reducing anemia burden
• Offers convenient, less frequent dosing

Side Effects

• Hypertension (high blood pressure)
• Headache
• Injection site pain or irritation
• Fever
• Nausea
• Vomiting
• Diarrhea
• Rash
• Thrombosis (blood clots)
• Seizures (rare)
• Allergic reactions
• Cough

Safety Measures

• Alcohol - Moderate alcohol consumption is generally permissible, but consult your doctor as it may affect overall health and treatment efficacy.
• Pregnancy - Consult your doctor before use during pregnancy. The benefits and risks should be carefully evaluated.
• Breastfeeding - Consult your doctor before use while breastfeeding. Limited data are available on its excretion into breast milk.
• Liver - Use with caution in patients with severe liver impairment. Regular monitoring of liver function may be advised.
• Kidney - This product is specifically for anemia of CKD. Close monitoring of hemoglobin and blood pressure is crucial.
• Lung - Generally considered safe, but monitor for symptoms of pulmonary embolism, especially in patients with a history of thrombosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.